

David J. Grainger et al.

Title:

PREVENTION AND TREATMENT OF CARDIOVASCULAR PATHOLOGIES WITH TAMOXIFEN

**ANALOGUES** 

Docket No.:

295.009US3

January 4, 2001

Serial No.: 09/754,775 Due Date: April 13, 2002 RECEIVED

Filed: Examiner:

Theodore Criares

Group Art Unit: 1617

APR 2 4 2002

Commissioner for Patents Washington, D.C. 20231

TECH CENTER 1603/2300

We are transmitting herewith the following attached items (as indicated with an "X"):

<u>X</u> A return postcard.

<u>x</u> Supplemental Preliminary Amendment including Clean Set of Pending Claims (31 Pages).

If an additional fee is required due to changes to the claims, the fee has been calculated as follows:

CLAIMS AS AMENDED						
	(1) Claims Remaining After Amendment		(2) Highest Number Previously Paid For	(3) Present Extra	Rate	Fee
TOTAL CLAIMS	102	-	121		x 18 =	\$0.00
INDEPENDENT CLAIMS	9		16		x 84 =	\$0.00
[ ] MULTIPLE DEPENDENT CLAIMS PRESENTED						\$0.00
TOTAL						\$0.00

Please consider this a PETITION FOR EXTENSION OF TIME for sufficient number of months to enter these papers and please charge any additional required fees or credit overpayment to Deposit Account No. 19-0743.

SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A.

P.O. Box 2938, Minneapolis, MN 55402 (612-373-6900)

Reg. No. 39,665

CERTIFICATE UNDER 37 CFR 1.8: The undersigned hereby certifies that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail, in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231, on this 12th day of April, 2002.

Name

**Customer Number 21186** 

SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A.

P.O. Box 2938, Minneapolis, MN 55402 (612-373-6900)

(GENERAL)

## COPY OF PAPERS ORIGINALLY FILED

"LUEIVEL

APR 2 4 2002

OTF E 12 2002

S/N 09/754,775

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

David J. Grainger et al.

**Examiner: Theodore Criares** 

Serial No.:

09/754,775

Group Art Unit: 1617

Filed:

January 4, 2001

Docket: 295.009US3

Title:

PREVENTION AND TREATMENT OF CARDIOVASCULAR

PATHOLOGIES WITH TAMOXIFEN ANALOGUES

## SUPPLEMENTAL PRELIMINARY AMENDMENT

Commissioner for Patents Washington, D.C. 20231

Sir:

In response to the Office Communication dated March 13, 2002, please amend the above-identified application as follows:

## In The Claims

Please substitute the claim set in the appendix entitled "Clean Version of Pending Claims" for the previously pending claim set

Please cancel claims 63, 65, 67-89, 95-116, and 118-157 without prejudice.

Please add the following claims:

158. (New) A therapeutic method comprising inhibiting non-aortal vascular smooth muscle cell proliferation associated with procedural vascular trauma comprising administering to a mammal, such as a human, subjected to said procedural vascular trauma an effective cytostatic antiproliferative amount of a compound of formula (I):

B)